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Our aim was to evaluate lipid peroxidation, expressed as thiobarbituric acid-reactive substances (TBARS), nitric oxide metabolites
(nitrite + nitrate) expressed as NO
𝑥
, and TBARS/NO
𝑥
ratio in a group of subjects with metabolic syndrome (MS). In this regard we
enrolled 106 subjects with MS defined according to the IDF criteria, subsequently subdivided into diabetic (DMS) and nondiabetic
(NDMS) and also into subjects with a low triglycerides/HDL-cholesterol (TG/HDL-C) index or with a high TG/HDL-C index.
In the entire group and in the four subgroups of MS subjects we found an increase in TBARS and NO
𝑥
levels and a decrease
in TBARS/NO
𝑥
ratio in comparison with normal controls. Regarding all these parameters no statistical difference between DMS
and NDMS was evident, but a significant increase in NO
𝑥
was present in subjects with a high TG/HDL-C index in comparison
with those with a low index. In MS subjects we also found a negative correlation between TBARS/NO
𝑥
ratio and TG/HDL-C
index. Considering the hyperactivity of the inducible NO synthase in MS, these data confirm the altered redox and inflammatory
status that characterizes the MS and suggest a link between lipid peroxidation, inflammation, and insulin resistance, evaluated as
TG/HDL-C index.
1. Introduction
Themetabolic syndrome (MS) is characterized by an elevated
cardiovascular morbidity and mortality [1].
A strong association between MS and oxidative stress
has been demonstrated [2, 3]. The end products of lipid
peroxidation, which refers to the oxidative degradation of
lipids resulting in cell membrane damage, are malondi-
aldehyde (MDA), 4-hydroxynonenal (HNE), and 4-oxy-2-
nonenal (ONE), obtained by the oxidation of polyunsaturated
fatty acids. Other systemic markers of lipid peroxidation are
oxidized low-density lipoprotein (oxLDL), isoprostanes, and
thiobarbituric acid-reactive substances (TBARS), which are
increased in MS subjects [4–10]. Plasma lipid peroxidation
products levels are higher in subjects with 5 MS components
compared with those with 2 or 3 MS components [11]. A
multivariate analysis, performed by Leiva et al., showed that
elevated levels of TBARS are associated with a 21-fold risk
for the development of MS [12]. OxLDLs are increased in
newly diagnosed MS subjects [13] and are also considered a
predictive biomarker for MS [14]. OxLDLs are significantly
correlated with coronary artery calcium measured using
computerized tomography and with greater internal carotid
intima-media thickness in MS subjects [15]. Recently, in
diabetic subjects with coronary artery disease, elevated serum
MDA-modified LDL (MDA-LDL) levels have been observed
and, in subjects withmore than 4MS criteria, a higherMDA-
LDL/LDL-cholesterol ratio has been found. MDA-LDLs are
correlated with lipid profile, C-reactive protein (CRP), and
adiponectin levels [16]. Also the urinary 8-epi-prostaglandin
F2𝛼 (8-epi-PGF2𝛼) is increased and significantly correlated
with CRP in MS subjects, underlining the close link between
oxidative stress and systemic inflammation [17].
Recently in a group of MS subjects we observed a marked
increase of the nitric oxide metabolites (NO
𝑥
), not associated
with the presence of diabetes mellitus (DM) [18]. Our data
were in agreement with other papers [19–21] that described
a NO
𝑥
increase in MS. The explanation of this finding is
ascribed to the degree of inflammation accompanying MS
that induces the expression of inducible nitric oxide synthase
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2014, Article ID 824756, 8 pages
http://dx.doi.org/10.1155/2014/824756
2 Oxidative Medicine and Cellular Longevity
(iNOS) by macrophages. As it is known, in addition, the
iNOS is activated by cytokines, such as TNF-𝛼, IL-1𝛽, and
interferon [22–24], even if in literature there are contrasting
data regarding the direct relationship betweenNO
𝑥
and some
of these cytokines [25–28].
In this reexamination of our group of MS subjects, we
calculated also the TBARS/NO
𝑥
ratio that, up to now, has
been evaluated in preeclampsia [29], in juvenile essential
hypertension [30], and in hypertensive adolescents with
obesity or uraemia [31, 32]. In MS the TBARS/NO
𝑥
ratio
may be considered as an integrated marker of plasma lipid
peroxidation and degree of inflammation.
In this study, we evaluated lipid peroxidation, expressed
as TBARS, nitric oxide metabolites (NO
𝑥
), and their ratio
(TBARS/NO
𝑥
) in a group of MS subjects subdivided accord-
ing to the presence or not of diabetes mellitus and also
according to the degree of insulin resistance, expressed
as triglycerides/HDL-cholesterol (TG/HDL-C) index; this
index, in fact, may be considered an indicator of insulin
resistance [33–35] its logarithm being inversely correlated
with insulin sensitivity measures, such as the homeostasis
model assessment and the quantitative insulin sensitivity
check index [36].
2. Subjects and Methods
We enrolled 106 subjects (45 women and 61 men, mean
age: 53.5 ± 8.9 years) with MS defined according to the
International Diabetes Federation criteria [37]. Subsequently,
MS subjects were subdivided, respectively, into diabetics
(DMS) (14 women and 29 men) and nondiabetics (NDMS)
(31 women and 32 men) and into MS subjects with low
(27 women and 26 men) or with high (18 women and
35 men) TG/HDL-C ratio. These two last subgroups of 53
subjects were selected according to the median value of the
TG/HDL-C ratio. The control group consisted of 41 subjects
(14 women and 27 men, mean age: 41.6 ± 7.9 years) selected
from the hospital staff; control subjects were free of medical
diseases as assessed by clinical history, physical examination,
electrocardiography, and routine hematological and urine
analysis. In all the participants cholesterol and triglycerides
were measured by standard enzymatic procedures, high-
density lipoprotein (HDL) cholesterol after phosphotungstic
acid/magnesium chloride precipitation and enzymatic deter-
mination of cholesterol, and low-density lipoprotein (LDL)
cholesterol was determined by the Friedewald formula.Mean
and S.D. of age, anthropometric profile, glycometabolic
pattern, lipid profile, and blood pressure values of the entire
group and of the four subgroups of MS subjects (subdivided
according to the presence of DM or to the TG/HDL-C ratio)
are shown in Tables 1 and 2.
At fasting blood samples were collected by venous punc-
ture from the antecubital vein of each subject and immedi-
ately transferred to glass tubes anticoagulatedwith EDTA-K3;
then we evaluated lipid peroxidation and NO metabolites.
2.1. Lipid Peroxidation. The oxidation of polyunsaturated
fatty acids was determined in plasma by the detection of the
thiobarbituric acid-reactive substances (TBARS) generated
by peroxidative processes, which include lipid peroxides and
MDA. The evaluation of TBARS was made by fluorimetry,
using the 1,1,3,3-tetramethoxypropane as standard [38].
2.2. NO Metabolites. Considering that in vivo NO has a
very short life (less than 0.1 sec) and it is converted into
nitrite (NO
2
−), which has a half-life of few minutes, and
into the more stable nitrate (NO
3
−), NO
𝑥
represents almost
only the nitrate concentration. In the laboratory method
adopted by us at first nitrate was converted into nitrite
by a nitrate reductase, and then nitrite was assessed by
spectrophotometry after the addition of the Griess reagent
[39].
2.3. Statistical Analysis. The values were expressed as means
± S.D. The difference between the control group and MS
subjects was evaluated according to Student’s 𝑡-test for
unpaired data. The comparison between control group and
MS subjects subdivided according to the presence or not of
DM and according to the TG/HDL-C index was performed
using the one-way analysis of variance (ANOVA), integrated
with Bonferroni’s multiple posttest.The values of TBARS and
NO
𝑥
and of TBARS/NO
𝑥
ratio were correlated with the age,
the anthropometric profile, the blood pressure values, and the
glycometabolic and lipid pattern using the linear regression
test. The null hypothesis was rejected for 𝑃 values less than
0.5.
3. Results
Examining the age, the anthropometric profile, the blood
pressure values, and the glycometabolic pattern of MS sub-
jects subdivided according to the presence or not of DM, we
observed (Table 2) that age, waist circumference, and blood
glucose levels were higher inDMS, while total cholesterol and
LDL-cholesterol were higher in NDMS.
Examining the same parameters in MS subjects sub-
divided according to the TG/HDL-C index (Table 2), we
observed that total cholesterol and triglycerides were in-
creased in the subgroup with high TG/HDL-C index and that
the HDL-cholesterol was increased in the subgroup with low
TG/HDL-C index.
In the entire group of MS subjects an increase in TBARS
and in NO
𝑥
levels and a marked decrease in TBARS/NO
𝑥
ratio were evident in comparison with normal controls
(Table 3). In the control group, as well as in the whole group
of MS subjects, no statistical correlation between TBARS
and NO
𝑥
was observed (data not shown). Subdividing MS
subjects into DMS and NDMS (Table 4) and also according
to the low or high TG/HDL-C index (Table 5), we found
an increase in TBARS and in NO
𝑥
levels and a decrease
in TBARS/NO
𝑥
ratio in all the subgroups compared with
normal controls. Employing the Bonferroni posttest, instead,
we found no significant difference between DMS and NDMS
regarding TBARS, NO
𝑥
, and TBARS/NO
𝑥
ratio (Table 4),
while we noted a significant increase in NO
𝑥
in subjects with
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Table 1
Mean ± S.D. Range
Waist circumference (cm) 106.7 ± 11.2 86–135
Body mass index (Kg/m2) 32.21 ± 4.53 22.5–45.2
Systolic blood pressure (mmHg) 132.1 ± 16.3 100–210
Diastolic blood pressure (mmHg) 81.2 ± 9.9 50–110
Fasting glucose (mg/dL) 114.3 ± 44.3 68–347
Total cholesterol (mg/dL) 213.9 ± 53.0 106–390
HDL-cholesterol (mg/dL) 40.4 ± 10.8 14–80
LDL-cholesterol (mg/dL) 133.2 ± 46.5 52.4–292.0
Triglycerides (mg/dL) 220.2 ± 147.8 52–759
TG/HDL index 6.399 ± 6.033 1.060–32.52
Means ± S.D. and range of the anthropometric profile, blood pressure values, and metabolic pattern in all MS subjects.
MS: metabolic syndrome.
Table 2
MS patients without
DM
MS patients with
DM
MS patients with low
TG/HDL index
MS patients with high
TG/HDL index
Waist circumference (cm) 102.8 ± 8.8 114.4 ± 11.7§ 106.7 ± 11.16 106.8 ± 11.46
Body mass index (Kg/m2) 31.5 ± 4.2 33.2 ± 5.0∗ 32.45 ± 4.55 31.94 ± 4.55
Systolic blood pressure (mmHg) 130.0 ± 13.3 136.0 ± 20.5 133.2 ± 18.8 131.1 ± 13.7
Diastolic blood pressure (mmHg) 82.2 ± 8.9 79.6 ± 11.4 80.5 ± 10.9 81.94 ± 8.9
Fasting glucose (mg/dL) 92.2 ± 10.3 147.5 ± 54.2§ 114.5 ± 39.7 114.2 ± 48.7
Total cholesterol (mg/dL) 228.0 ± 48.3 193.1 ± 53.1§ 201.2 ± 40.8 226.6 ± 60.6†
HDL-cholesterol (mg/dL) 39.7 ± 9.3 41.4 ± 12.8 46.9 ± 9.3 33.9 ± 8.1‡
LDL-cholesterol (mg/dL) 147.9 ± 45.8 112.8 ± 39.7§ 123.5 ± 37.5 143.0 ± 58.7
Triglycerides (mg/dL) 231.0 ± 145.9 204.2 ± 150.9 137.4 ± 42.6 302.9 ± 168.4‡
TG/HDL index 6.739 ± 6.190 5.900 ± 5.832 3.00 ± 0.95 9.80 ± 7.00‡
Means ± S.D. of the anthropometric profile, blood pressure values, and metabolic pattern in MS patients subdivided, respectively, into nondiabetics and
diabetics and into patients with low and high TG/HDL index.
∗
𝑃 < 0.05; §𝑃 < 0.001 versus MS patients without DM (Student’s 𝑡-test).
†
𝑃 < 0.05; ‡𝑃 < 0.001 versus MS patients with low TG/HDL index (Student’s 𝑡-test).
MS: metabolic syndrome.
DM: diabetes mellitus.
Table 3
Control subjects All MS patients
TBARS (nmol/mL) 5.902 ± 1.211 8.983 ± 0.722§
NO
𝑥
(nmol/mL) 28.07 ± 18.83 79.82 ± 29.22§
TBARS/NO
𝑥
ratio 0.363 ± 0.311 0.128 ± 0.049§
Means± S.D. of TBARS, NO
𝑥
, and TBARS/NO
𝑥
ratio in control subjects and
in all MS patients.
§
𝑃 < 0.001 versus control subjects (Student’s 𝑡-test).
MS: metabolic syndrome.
TBARS: thiobarbituric acid-reactive substances.
NO
𝑥
: nitric oxide metabolites (nitrite + nitrate).
a high TG/HDL-C index in comparisonwith those with a low
index (Table 5).
In the entire group of MS subjects we found a pos-
itive correlation between TBARS and TG/HDL-C index
(𝑟 = 0.250; 𝑃 < 0.01) and between NO
𝑥
and TG/HDL-C
index (𝑟 = 0.321; 𝑃 < 0.001) and a negative correlation
between TBARS/NO
𝑥
ratio and TG/HDL-C index (𝑟 =
−0.238; 𝑃 < 0.05) (Figure 1).
Examining the linear regression among TBARS, age,
anthropometric profile, blood pressure values, and gly-
cometabolic pattern, in the entire group of MS subjects we
observed only a positive correlation between TBARS and
fasting blood glucose level (𝑟 = 0.206; 𝑃 < 0.02).
Examining the linear regression among NO
𝑥
and all the
parameters previously considered, in the entire group of MS
subjects we found only a positive correlation between NO
𝑥
and triglycerides (𝑟 = 0.344; 𝑃 < 0.001).
Examining instead the linear regression among
TBARS/NO
𝑥
ratio and the above-mentioned characteristics
of the MS subjects, we found in the whole group only a neg-
ative correlation between TBARS/NO
𝑥
and triglycerides
(𝑟 = −0.259; 𝑃 < 0.007).
4. Discussion
The analysis of the data concerning the evaluation of lipid
peroxidation, nitric oxide metabolites, and their ratio in MS
shows some aspects that deserve to be underlined.
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Table 4
Control subjects MS patients without DM MS patients with DM 𝐹
TBARS (nmol/mL) 5.902 ± 1.211 8.834 ± 0.628§ 9.200 ± 0.801§ 185.81
NO
𝑥
(nmol/mL) 28.07 ± 18.83 80.99 ± 33.93§ 78.10 ± 20.76§ 55.11
TBARS/NO
𝑥
ratio 0.363 ± 0.311 0.129 ± 0.057§ 0.125 ± 0.033§ 28.51
Means ± S.D. of TBARS, NO
𝑥
, and TBARS/NO
𝑥
ratio in control subjects and in MS patients subdivided into nondiabetics and diabetics.
1
𝑃 < 0.001 (ANOVA).
§
𝑃 < 0.001 versus control subjects (Bonferroni’s test).
MS: metabolic syndrome.
DM: diabetes mellitus.
TBARS: thiobarbituric acid-reactive substances.
NO
𝑥
: nitric oxide metabolites (nitrite + nitrate).
Table 5
Control subjects MS patients with low TG/HDL index MS patients with high TG/HDL index 𝐹
TBARS (nmol/mL) 5.902 ± 1.211 8.902 ± 0.581§ 9.063 ± 0.838§ 179.61
NO
𝑥
(nmol/mL) 28.07 ± 18.83 72.67 ± 27.34§ 86.97 ± 29.54§# 61.91
TBARS/NO
𝑥
ratio 0.363 ± 0.311 0.140 ± 0.057§ 0.115 ± 0.035§ 28.91
Means ± S.D. of TBARS, NO
𝑥
, and TBARS/NO
𝑥
ratio in control subjects and in MS patients subdivided according to the TG/HDL index.
1
𝑃 < 0.001 (ANOVA).
§
𝑃 < 0.001 versus control subjects (Bonferroni’s test).
#
𝑃 < 0.05 versus MS patients with low TG/HDL index (Bonferroni’s test).
MS: metabolic syndrome.
TBARS: thiobarbituric acid-reactive substances.
NO
𝑥
: nitric oxide metabolites (nitrite + nitrate).
The first point concerns the asymmetrical increase in
TBARS and NO
𝑥
in the entire group of MS subjects; in
fact, the TBARS increase is of 52.2% while the NO
𝑥
increase
is of 184.4%; therefore, the TBARS/NO
𝑥
ratio is markedly
decreased (−64.7%) in comparison with normal controls.
This asymmetrical behavior might explain the lack of corre-
lation between TBARS and NO
𝑥
observed by us, differently
from others, who found a positive correlation between
hydroperoxide levels and NO
𝑥
in MS [40]. In this regard, it
must be considered that we evaluated a parameter of lipid
peroxidation (TBARS) that includes not only hydroperoxides
but also malondialdehyde.
The second point concerns the different behavior of
TBARS, NO
𝑥
, and TBARS/NO
𝑥
ratio in MS subjects subdi-
vided according to the presence or not of DM or according
to the TG/HDL-C index. In fact, the subdivision of MS
subjects into DMS and NDMS does not show any difference
in these parameters, while the subdivision according to
the TG/HDL-C index shows a difference in NO
𝑥
between
low TG/HDL-C index subjects and high TG/HDL-C index
subjects.This behavior is imputable to themarked increase in
NO
𝑥
observed in the subgroup where a condition of greater
insulin resistance is evident.
The third point that needs to be investigated is the
bidirectional role played by the insulin resistance in lipid
peroxidation and NO
𝑥
. The pivotal role of the insulin resis-
tance in MS is well known and the results observed in this
research seem to confirm this assumption. In the entire
group of MS subjects a positive correlation between TBARS
and TG/HDL-C index and between NO
𝑥
and TG/HDL-
C index is evident, suggesting a close link between the
degree of insulin resistance, the lipid peroxidation, and
the synthesis of NO
𝑥
. In other clinical conditions that are
included among the principal criteria for MS, such as obesity
[25] and arterial hypertension [41], a significant correlation
between NO
𝑥
and insulin levels was found. However, no
correlation between NO
𝑥
and insulin resistance (evaluated
as steady state plasma glucose) has been observed in DM
subjects [42]. In nondiabetic hypercholesterolemic subjects
a positive correlation between the urinary 8-epi-PGF2𝛼 and
theHOMA-IRwas observed [43]. Fromour data we observed
an interesting negative correlation betweenTG/HDL-C index
and TBARS/NO
𝑥
ratio, which underlines how the reduction
of TBARS/NO
𝑥
ratio is associated with the degree of insulin
resistance.
All the aspects described in this third point call the atten-
tion to the link between lipid peroxidation, iNOS activity,
and insulin resistance. In animal models [44, 45] the iNOS
seems to play an indirect role in the pathogenesis of the
insulin resistance in peripheral tissues, and in particular in
the skeletal muscle. Similarly, recent research on experimen-
tal models has underlined how some bioproducts of lipid
peroxidation, such as HNE and ONE, are able to induce
structural and functional changes in human insulin [46] and
how HNE causes insulin resistance [47]. The role played by
lipid peroxidation in the insulin resistance development has
been suggested also in sedentary adults [48], in which lipid
peroxides seem to act on the skeletal muscle. Recently [49]
other authors have hypothesized that HNE and oxysterols
may be the link between the adipose tissue dysfunction and
the abnormality of glucose homeostasis.
In agreement with our data, some authors observed
in DM subjects a correlation between TBARS and fasting
glucose level [50]. Differently from others, who found a
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Figure 1: Correlations between TG/HDL index and, respectively, TBARS, NO
𝑥
, and TBARS/NO
𝑥
ratio in MS patients.
positive correlation between oxLDL, age, systolic blood pres-
sure, and body mass index (BMI) [51], a positive correlation
between MDA and BMI [52], and a positive correlation
between lipoperoxides and systolic blood pressure [53], we
did not note any correlation between TBARS, age, anthro-
pometric parameters, and blood pressure values. In this
research no correlation between TBARS, total cholesterol,
LDL-cholesterol, and HDL-cholesterol was noted, while
we observed a negative correlation between TBARS and
triglycerides, considered by us occasional and physiologically
inexplicable. Other authors in hypercholesterolemic subjects
found a positive correlation between MDA, total cholesterol,
and LDL-cholesterol and a negative correlation between
MDA and HDL-C [54]. Regarding the NO
𝑥
we observed
neither correlation between NO
𝑥
and age nor correlation
between NO
𝑥
, anthropometric profile, and blood pressure
values, differently fromother authors [55–57]. In addition, we
did not find any correlation between NO
𝑥
and lipid profile,
although some significant correlations between NO
𝑥
and
lipid parameters have been observed in adolescent subjects
[58]. The positive correlation between NO
𝑥
and triglycerides
found by us in these subjects agrees with that reported by
other authors in postmenopausal women with MS [21] and
in healthy population [56], but it has not been observed in
normal-weight obese syndrome [28].
From the analysis of the data reported in this study, the
data reported in this study clearly confirmed the abnormality
of the oxidative status accompanying the MS, as previously
described by us in the same group ofMS subjects, inwhichwe
have examined the behavior of NO
𝑥
[18], and also the protein
oxidation [59] and the total antioxidant status (in press).
5. Conclusions
In conclusion, the simultaneous examination of TBARS,
NO
𝑥
, and TBARS/NO
𝑥
ratio in MS subjects, subdivided,
respectively, according to the presence of DM or to the
TG/HDL-C index, shows a different trend of these parame-
ters in relation to the subdivision criteria and, in particular, a
significant positive association between NO
𝑥
and the degree
of insulin resistance.This datum, like other aspects discussed
in the text, might suggest considering the possible use of the
antioxidant treatment in MS subjects in order to attenuate
the insulin resistance that seems to affect the peripheral
tissues, and in particular the skeletal muscle. In this regard,
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up to now, several molecules, such as vitamins C and E and
flavonoids [49], 𝛼-lipoic acid, 𝛼-tocopherol, glutathione, N-
acetylcysteine, coenzyme Q10, and taurine [60], have been
employed to prevent or to treat MS and associated diseases.
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